Evidence map›Paper›PMID 36545045›Full record

ArticleComplex psychiatry2022

Identifying High-Risk Comorbidities Associated with Opioid Use Patterns Using Electronic Health Record Prescription Data.

Mariela V Jennings, Hyunjoon Lee, Daniel B Rocha, Sevim B Bianchi, Brandon J Coombes, Richard C Crist, Annika B Faucon, Yirui Hu, Rachel L Kember, Travis T Mallard and 9 more

Open access · greenAbstract read
In one paragraph

Article in Complex psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 1 country.

Mariela V JenningsDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA.
Hyunjoon LeePsychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Daniel B RochaPhenomic Analytics and Clinical Data Core, Geisinger, Danville, Pennsylvania, USA.
Sevim B BianchiDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA.
Brandon J CoombesDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Richard C CristDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Annika B FauconVanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Yirui HuDepartment of Population Health Sciences, Geisinger, Danville, Pennsylvania, USA.
Rachel L KemberDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Travis T MallardPsychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Maria NiarchouVanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Melissa N PoulsenDepartment of Population Health Sciences, Geisinger, Danville, Pennsylvania, USA.
Peter StraubVanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Richard D UrmanDepartment of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Colin G WalshDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Lea K DavisDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jordan W SmollerPsychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Vanessa TroianiGeisinger Clinic, Geisinger, Danville, Pennsylvania, USA.
Sandra Sanchez-RoigeDepartment of Psychiatry, University of California San Diego, La Jolla, California, USA.
Vanderbilt University Medical Center · USGeisinger Health System · USMassachusetts General Hospital · USUniversity of California San Diego · USGeisinger Medical Center · USUniversity of Pennsylvania · USBrigham and Women's Hospital · USMayo Clinic in Florida · US

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Sequencing CoreP50DA037844 · NIDA · UNIVERSITY OF CHICAGO · PI POLESSKAYA, OKSANA O · 2014 to 2023
$27.4M
Supplemental Application for Clinical and Genetic Risk Profile of Opioid Use DisorderR01DA044015 · NIDA · GEISINGER CLINIC · PI BERRETTINI, WADE H, ROBISHAW, JANET D · 2017 to 2021
$4.5M
PsycheMERGE: Leveraging electronic health records and genomics for mental health researchR01MH118233 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI DAVIS, LEA K, SMOLLER, JORDAN W · 2019 to 2022
$3.1M
Partners Healthcare Training Program in Precision and Genomic MedicineT32HG010464 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI HEIDI L REHM, JORDAN W SMOLLER · 2019 to 2026
$3.1M
Training Program on Genetic Variation and Human PhenotypesT32GM080178 · NIGMS · VANDERBILT UNIVERSITY · PI COX, NANCY J, SAMUELS, DAVID C · 2007 to 2021
$3.1M
Distinguishing Clinical and Genetic Risk of Suicidal Ideation from Attempts to Inform PreventionR01MH121455 · NIMH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RUDERFER, DOUGLAS, WALSH, COLIN GEORGE · 2020 to 2024
$2.7M
Building Bridges to Allow Cross-species Translational genetics for the Study of AddictionDP1DA054394 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SANCHEZ ROIGE, SANDRA · 2021 to 2025
$2.4M
2/4: Leveraging EHR-linked biobanks for deep phenotyping, polygenic risk score modeling, and outcomes analysis in psychiatric disordersR01MH121924 · NIMH · MAYO CLINIC ROCHESTER · PI BIERNACKA, JOANNA M · 2019 to 2024
$2.0M
Integrating signals of suicide risk from DoD and VHA data to improve upon suicide risk prevention strategies for combat VeteransR01MH120122 · NIMH · UNIVERSITY OF COLORADO DENVER · PI ADAMS, RACHEL SAYKO, BRENNER, LISA A · 2019 to 2022
$1.9M
2/2 Leveraging electronic health records for pharmacogenomics of psychiatric diordersR01MH116269 · NIMH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RUDERFER, DOUGLAS, WALSH, COLIN GEORGE · 2019 to 2022
$1.7M
Reducing ethnic and language disparities in Spanish-speaking patients who receive opioids for postsurgical painR34DA048268 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHNIPPER, JEFFREY LAWRENCE, URMAN, RICHARD D. · 2020 to 2021
$984k
NCATS NIH HHS UL1 TR000445NHGRI NIH HHS T32 HG010464NIAAA NIH HHS K01 AA028292NIDA NIH HHS DP1 DA054394NIDA NIH HHS K01 DA049903NIDA NIH HHS P50 DA037844NIDA NIH HHS R01 DA044015NIDA NIH HHS R34 DA048268NIGMS NIH HHS T32 GM080178NIMH NIH HHS R01 MH116269NIMH NIH HHS R01 MH118233NIMH NIH HHS R01 MH120122NIMH NIH HHS R01 MH121455NIMH NIH HHS R01 MH121924
6 · The paper itself

Abstract

Introduction: Opioid use disorders (OUDs) constitute a major public health issue, and we urgently need alternative methods for characterizing risk for OUD. Electronic health records (EHRs) are useful tools for understanding complex medical phenotypes but have been underutilized for OUD because of challenges related to underdiagnosis, binary diagnostic frameworks, and minimally characterized reference groups. As a first step in addressing these challenges, a new paradigm is warranted that characterizes risk for opioid prescription misuse on a continuous scale of severity, i.e., as a continuum. Methods: Across sites within the PsycheMERGE network, we extracted prescription opioid data and diagnoses that co-occur with OUD (including psychiatric and substance use disorders, pain-related diagnoses, HIV, and hepatitis C) for over 2.6 million patients across three health registries (Vanderbilt University Medical Center, Mass General Brigham, Geisinger) between 2005 and 2018. We defined three groups based on levels of opioid exposure: no prescriptions, minimal exposure, and chronic exposure and then compared the comorbidity profiles of these groups to the full registries and to those with OUD diagnostic codes. Results: Our results confirm that EHR data reflects known higher prevalence of substance use disorders, psychiatric disorders, medical, and pain diagnoses in patients with OUD diagnoses and chronic opioid use. Comorbidity profiles that distinguish opioid exposure are strikingly consistent across large health systems, indicating the phenotypes described in this new quantitative framework are robust to health systems differences. Conclusion: This work indicates that EHR prescription opioid data can serve as a platform to characterize complex risk markers for OUD using existing data.

Indexed as

Electronic health recordsOpioidsOpioid use disorderPrescription dataSubstance use disorders

Identifiers

PMID36545045
PMCPMC9669950
OpenAlexW4282006935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.